127 related articles for article (PubMed ID: 11549508)
1. Increased Fas ligand expression in the tumor tissue and serum of patients with testicular germ cell tumors with seminomatous elements.
Hara S; Miyake H; Nakamura I; Arakawa S; Kamidono S; Hara I
Urology; 2001 Sep; 58(3):471-6. PubMed ID: 11549508
[TBL] [Abstract][Full Text] [Related]
2. Expression of Fas and Fas ligand in human testicular germ cell tumours.
Baldini E; Ulisse S; Marchioni E; Di Benedetto A; Giovannetti G; Petrangeli E; Sentinelli S; Donnorso RP; Reale MG; Mottolese M; Gandini L; Lenzi A; D'Armiento M
Int J Androl; 2009 Apr; 32(2):123-30. PubMed ID: 17916181
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum soluble Fas ligand is a promising marker of testicular toxicity induced by epirubicin in rats.
Geng J; Fan J; Jiang HW; Fang ZJ; Wang X; Sun JL; Ding Q; Chen G
Toxicol Lett; 2009 Apr; 186(2):96-103. PubMed ID: 19429229
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system.
Wang XZ; Chen XC; Chen YX; Zhang LJ; Li D; Chen FL; Chen ZX; Chen HY; Tao QM
World J Gastroenterol; 2003 Dec; 9(12):2671-5. PubMed ID: 14669310
[TBL] [Abstract][Full Text] [Related]
5. Significance of serum soluble Fas ligand in patients with bladder carcinoma.
Mizutani Y; Hongo F; Sato N; Ogawa O; Yoshida O; Miki T
Cancer; 2001 Jul; 92(2):287-93. PubMed ID: 11466681
[TBL] [Abstract][Full Text] [Related]
6. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma.
Ichikura T; Majima T; Uchida T; Okura E; Ogawa T; Mochizuki H
Oncol Rep; 2001; 8(2):311-4. PubMed ID: 11182046
[TBL] [Abstract][Full Text] [Related]
7. Soluble form of fas and fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia.
Kuwano K; Kawasaki M; Maeyama T; Hagimoto N; Nakamura N; Shirakawa K; Hara N
Chest; 2000 Aug; 118(2):451-8. PubMed ID: 10936140
[TBL] [Abstract][Full Text] [Related]
8. The fas and fas ligand pathways in liver allograft tolerance.
Pan TL; Goto S; Lin YC; Lord R; Chiang KC; Lai CY; Chen YS; Eng HL; Cheng YF; Tatsuma T; Kitano S; Lin CL; Chen CL
Clin Exp Immunol; 1999 Oct; 118(1):180-7. PubMed ID: 10540176
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the Fas/FasL pathway in the pathogenesis of germ cell tumours of the adult testis.
Kersemaekers AM; van Weeren PC; Oosterhuis JW; Looijenga LH
J Pathol; 2002 Apr; 196(4):423-9. PubMed ID: 11920738
[TBL] [Abstract][Full Text] [Related]
10. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Kuwano K; Maeyama T; Inoshima I; Ninomiya K; Hagimoto N; Yoshimi M; Fujita M; Nakamura N; Shirakawa K; Hara N
Respirology; 2002 Mar; 7(1):15-21. PubMed ID: 11896896
[TBL] [Abstract][Full Text] [Related]
11. Fas and Fas-ligand expression in seminomatous testes.
Braendstrup O; Bols B; Jensen L
APMIS; 1999 Apr; 107(4):431-6. PubMed ID: 10230699
[TBL] [Abstract][Full Text] [Related]
12. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis.
Hashimoto H; Tanaka M; Suda T; Tomita T; Hayashida K; Takeuchi E; Kaneko M; Takano H; Nagata S; Ochi T
Arthritis Rheum; 1998 Apr; 41(4):657-62. PubMed ID: 9550474
[TBL] [Abstract][Full Text] [Related]
13. Examination of soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with burns.
Yamada Y; Endo S; Nakae H; Makabe H; Sato N; Wakabayashi G; Kitamura M; Inada K; Sato S
Burns; 2003 Dec; 29(8):799-802. PubMed ID: 14636754
[TBL] [Abstract][Full Text] [Related]
14. Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma.
Redondo P; Solano T; VAzquez B; Bauza A; Idoate M
Br J Dermatol; 2002 Jul; 147(1):80-6. PubMed ID: 12100188
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of soluble Fas ligand in patients with silicosis.
Tomokuni A; Otsuki T; Isozaki Y; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A
Clin Exp Immunol; 1999 Dec; 118(3):441-4. PubMed ID: 10594565
[TBL] [Abstract][Full Text] [Related]
17. Increased serum levels of soluble Fas in progressive B-CLL.
Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
Eur J Haematol; 2001 May; 66(5):342-6. PubMed ID: 11422415
[TBL] [Abstract][Full Text] [Related]
18. Circulating soluble Fas ligand in patients with gastric carcinoma.
Tsutsumi S; Kuwano H; Shimura T; Morinaga N; Mochiki E; Asao T
Cancer; 2000 Dec; 89(12):2560-4. PubMed ID: 11135216
[TBL] [Abstract][Full Text] [Related]
19. Expression of FasL and Fas protein and their soluble form in patients with hypersensitivity pneumonitis.
Kuwano K; Hagimoto N; Kawasaki M; Nakamura N; Shirakawa K; Maeyama T; Hara N
Int Arch Allergy Immunol; 2000 Jul; 122(3):209-15. PubMed ID: 10899765
[TBL] [Abstract][Full Text] [Related]
20. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
